Clinical Trials Logo

Hepatic Impairment clinical trials

View clinical trials related to Hepatic Impairment.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05490030 Withdrawn - Hepatic Impairment Clinical Trials

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Start date: March 6, 2025
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155. The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.

NCT ID: NCT04759846 Withdrawn - Metastatic Melanoma Clinical Trials

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Start date: January 21, 2021
Phase: Phase 1
Study type: Interventional

Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation. The main objective of this study is to find a safe and effective dose of encorafenib in combination with binimetinib for patients who have BRAF-mutant metastatic or unresectable melanoma with hepatic dysfunction (i.e. moderate or severe impairment).

NCT ID: NCT03813979 Withdrawn - HIV-1-infection Clinical Trials

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

POLO
Start date: November 15, 2020
Phase: Phase 4
Study type: Interventional

This is an open-label, parallel-group, nonrandomized, multi-centre, phase-IV, single dose trial in 8 HIV-seronegative subjects with severe hepatic impairment and 8 matched controls to assess the pharmacokinetics of a single dose of 50mg of dolutegravir in subjects with severe hepatic impairment.

NCT ID: NCT03499041 Withdrawn - Hepatic Impairment Clinical Trials

A Study of LY3314814 in Participants With Liver Impairment

Start date: June 2018
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.

NCT ID: NCT03277755 Withdrawn - Hepatic Impairment Clinical Trials

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Start date: September 11, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK) of AL-335, odalasvir (ODV) and its metabolites ALS-022399 and ALS-022227, after a single oral dose of ODV and AL-335 respectively, in participants with moderately impaired hepatic function compared to participants with normal hepatic function. Also to evaluate the steady-state PK of AL-335 and its metabolites ALS-022399 and ALS-022227, ODV and simeprevir (SMV) after multiple oral doses of the combination of AL-335+ODV+SMV, in participants with moderately impaired hepatic function compared to participants with normal hepatic function.

NCT ID: NCT02985632 Withdrawn - Hepatic Impairment Clinical Trials

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Start date: January 11, 2017
Phase: Phase 1
Study type: Interventional

An oral dose of BMS-986141 administered in Hepatic Impairment and Healthy Participants to evaluate pharmacokinetics in this patient population.